You do not gain weight on Cabotegravir and Rilpivirine as Cabenuva and Rilpivirine do not cause weight gain..
Cabotegravir is owned by the ViiV Healthcare group of companies and is also sold under the names of Cabenuva in Canada and Vocabria and Rekaymbys in the EU.
Cabotegravir costs as much as $22,200.00 per year which is 185 times higher in cost than the $60.00 to $119.00 estimated cost effectiveness threshold for middle income families.
When used for HIV treatment, cabotegravir is always used with the HIV medicine rilpivirine (brand name: Edurant).
For short-term PrEP to reduce the risk of HIV infection in adults and adolescents who weigh at least 77 lb (35 kg), are HIV negative, and are at risk of getting HIV.
Cabotegravir is in a class of medications called HIV integrase inhibitors.
It works by decreasing the amount of HIV in the blood.
Although cabotegravir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer.
It is recommended that people who receive their every-2-month injections of cabotegravir on the same date every other month, making the Target Treatment Date fall between the 1st and 28th day of every 2 months to help ensure consistency. An optional oral lead-in can be used to assess tolerability with CABENUVA.
CAB-LA or cabotegravir could be self-administered by individuals who are already accustomed to self-injection for other health needs, but lab tests and other monitoring still required.
Cabotegravir for HIV prevention in cisgender men and transgender women.
These publications reported a 66% reduced risk of HIV acquisition for long-acting compared with daily oral PrEP in the prespecified primary analysis.